Global Cases on HIV Medicines

Since 2006, I-MAK has challenged ten patents on four HIV medicines. As a result, prices have fallen 51-89%.
Read case details below.

ABACAVIR

India: Patent on Salt

Case Status: Filed July 2006. Withdrawal of patent application within a year of opposition submitted, originator price reduced by 31%, generics were able to compete and prices come down over time to 77% of the original originator price.

LOPINAVIR/RITONAVIR

European Patent Office: Heat Stable Formation

Case Status: Filed in 2012.

European Patent Office: Heat Stable Formation

Case Type: Pre-grant observation filed by other parties
Case Status: Filed in 2007. Patent granted in 2008. While we lost this case, generics and multinationals subsequently contested the patent because the evidence I-MAK raised in its challenge paved the way.

India: Polymorph

Case Status: Filed in 2006. The patent application was rejected in 2010.

India: Polymorph

Case Status: Filed in 2006. The patent application was rejected in 2011.

India: Heat Stable Tablet Formulation

Case Status: Filed in August 2007. The patent application was rejected in 2011.

India: Soft-gel Capsule Formulation

Case Status: Filed in 2006. Abbvie abandoned the patent application within a few months.

NEVIRAPINE

India: Syrup Formulation

Case Status: Filed in 2006. Patent was rejected in June 2008.

TENOFOVIR

India: Prodrug

Case Status: Filed in 2006. Gilead offered a license to produce it at lowest cost within months of filing; patent application was rejected in September 2009.

India: Salt Compound for Formulation

Case Status: Filed in 2006. Gilead offered a license to produce it at lowest cost within months of filing; patent application was rejected in September 2009.

 

Join us to stay updated
and help make lifesaving medicines accessible to all